checkAd
    Startseite > Aktien > Travere Thereapeutics > Nachrichten
    Travere Thereapeutics
    Aktie
    ISIN: US89422G1076 WKN: A2QHYP SYM: TVTX Land USA
    Zur Watchlist hinzufügen Zum Portfolio hinzufügen
    7,3400
     
    USD
    +3,82 %
    +0,2700 USD
    Letzter Kurs 02:00:00 Nasdaq
    Geldkurs
    12.06.24
    7,3100
     
    USD
    7.900 STK
    Briefkurs
    12.06.24
    7,3300
     
    USD
    700 STK

    Travere Thereapeutics Aktie kaufen

    Kauf
    Verkauf

    Neueste Nachrichten

    Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    11.06.24 · globenewswire · Travere Thereapeutics
    Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    15.05.24 · globenewswire · Travere Thereapeutics
    Travere Therapeutics to Present at National Kidney Foundation Spring Clinical Meetings and the 61st European Renal Association Congress
    09.05.24 · globenewswire · Travere Thereapeutics
    Travere Therapeutics to Present at Upcoming Investor Conferences
    08.05.24 · globenewswire · Travere Thereapeutics
    Travere Therapeutics Reports First Quarter 2024 Financial Results
    06.05.24 · globenewswire · Travere Thereapeutics
    Travere Therapeutics to Report First Quarter 2024 Financial Results
    29.04.24 · globenewswire · Travere Thereapeutics
    Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI (sparsentan) for the treatment of IgA Nephropathy
    24.04.24 · globenewswire · Travere Thereapeutics
    Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders and Genetic Metabolic Dieticians International
    04.04.24 · globenewswire · Travere Thereapeutics
    Travere Therapeutics to Present Abstracts on FILSPARI (sparsentan) in IgA Nephropathy at World Congress of Nephrology and the American Nephrology Nurses Association
    03.04.24 · globenewswire · Travere Thereapeutics
    Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    13.03.24 · globenewswire · Travere Thereapeutics
    Travere Therapeutics Submits Supplemental New Drug Application to the U.S. Food and Drug Administration Seeking Full Approval of FILSPARI (sparsentan) for the Treatment of IgA Nephropathy (IgAN)
    11.03.24 · globenewswire · Travere Thereapeutics
    Travere Therapeutics to Present at Upcoming Investor Conferences
    26.02.24 · globenewswire · Travere Thereapeutics